John Leonard, Intellia CEO
November 2, 2023 11:18 AM EDT
R&D
Cell/Gene Tx

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Lei Lei Wu

News Reporter

In­tel­lia on Thurs­day pre­sent­ed new re­sults for its gene edit­ing treat­ment in 65 pa­tients with AT­TR amy­loi­do­sis — a con­di­tion in which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health ...

David Bak­er's lab makes en­zymes with AI, open­ing up the pos­si­bil­i­ty of more pre­cise gene-edit­ing tools

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Agios’ Pyrukynd suc­ceeds in key tri­al of rare red blood cell dis­or­der in kids

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times